Sarah Faircliffe, a consultant in our International Life Sciences Sector Group, was recently featured in the October 2012 issue of Scrip Regulatory Affairs. Sarah has written an overview on the transparency initiatives at the world's two key drug regulatory agencies. She summarises the implications for drug companies of recent moves at the European Medicines Agency and takes a look at what the future might bring.
Read the full article here (PDF)
Follow us on Twitter